Encyclopedia of Cancer

Living Edition
| Editors: Manfred Schwab

Myeloablative Megatherapy

  • Bernhard Kremens
Living reference work entry
DOI: https://doi.org/10.1007/978-3-642-27841-9_3930-2

Synonyms

Definition

The term “myeloablative megatherapy” describes a strategy of anticancer chemotherapy, in which the dose of drugs is increased to the extent that myelosuppression as a side effect will not recover by itself. To restore the patient’s hematopoiesis, his own blood stem cells are harvested and frozen before the high-dose chemotherapy and thawed and reinfused thereafter.

The alternative to autologous stem cell transplantation is allogenic stem cell transplantation; this means that a healthy donor provides the cells to restore the patient’s hematopoiesis.

Characteristics

Therapeutic Concept

Anticancer drugs are not dosed according to maximal damage to the cancer cell, but to keep their toxicity within limits tolerable for the patient. The amount which can safely be given is usually less than that which would exhaust the drug’s potential...

Keywords

Stem Cell Transplantation Dose Escalation Minimal Residual Disease Autologous Stem Cell Transplantation Blood Stem Cell 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.
This is a preview of subscription content, log in to check access.

References

  1. Berthold F, Boos J, Burdach S et al (2005) Myeloablative megatherapy with autologous stem-cell rescue versus oral maintenance chemotherapy as consolidation treatment in patients with high-risk neuroblastoma. A randomised controlled trial. Lancet Oncol 6:649–658CrossRefPubMedGoogle Scholar
  2. Ladenstein R, Pötschger U, Hartmann O et al (2008) 28 years of high-dose therapy and SCT for neuroblastoma in Europe: lessons from more than 4000 procedures. Bone Marrow Transplant 41:S118–S127CrossRefPubMedGoogle Scholar
  3. Nieboer P, de Vries EG, Mulder NH et al (2005) Relevance of high-dose chemotherapy in solid tumors. Cancer Treat Rev 31(3):210–225CrossRefPubMedGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2014

Authors and Affiliations

  1. 1.Department of Pediatric Hematology, Oncology and Respiratory MedicineUniversity Hospitals of EssenEssenGermany